CompletedNCT00014001

Long-term comparison of antipsychotic medicines for schizophrenia

About this title

Medication studyAges 18–65United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Chula Vista and 53 more locationsSee all locations and recruitment
Study phase: Phase 4

Study clarity

Study start dateDecember 2000

Recruitment status: Completed
Enrollment listed in the registry: 1,600
Sponsor: National Institute of Mental Health (NIMH)
Sponsor type: Government agency
Study type: Drug
Intervention type: Drug
Study phase: Phase 4
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT00014001
Official title: Show the full official title
Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)

Completed

Chula Vista · Los Angeles · Orange

44 more locations

FAQ

Who is behind this study?

The study sponsor is National Institute of Mental Health (NIMH), a government agency.

Did this study involve medication?

Yes. The study involved medication, including perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine and fluphenazine decanoate.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.